

Income and Expenditure Budget
April 1, 2026 – March 31, 2027

Unit: YEN)

Account	FY 2026 Budget		
	Public Interest Purpose	Corporate Account	Total
I General Net Assets Change			
1. Ordinary Change			
(1) Ordinary Revenue			
Interest from Basic Fund	8,530,600	4,593,400	13,124,000
Interest from Basic Fund	8,530,600	4,593,400	13,124,000
Others	△ 1,638,320	0	△ 1,638,320
Interest from Investment Fund	△ 1,710,320	0	△ 1,710,320
Other Interest Received	72,000	0	72,000
Ordinary Revenue Total	6,892,280	4,593,400	11,485,680
(2) Ordinary Expense			
Project Expense	70,603,500		70,603,500
Director's Remuneration	1,920,000		1,920,000
Meeting	500,000		500,000
Travel & Transportation	500,000		500,000
Postage & Communication	280,000		280,000
Office Supply	20,000		20,000
Printing	400,000		400,000
Heat, Light & Water	28,000		28,000
Rent	2,008,000		2,008,000
Remuneration	4,050,000		4,050,000
Commission Charge	25,000		25,000
Grant	(37,000,000)		(37,000,000)
Novartis Research Grant	35,000,000		35,000,000
Research Meeting Grant	2,000,000		2,000,000
Remuner Annual Report Publication	400,000		400,000
Outsourcing Expense	23,422,500		23,422,500
Others	50,000		50,000
Administrative Expense		11,348,000	11,348,000
Director's Remuneration		1,480,000	1,480,000
Meeting		1,100,000	1,100,000
Travel & Transportation		400,000	400,000
Postage & Communication		325,000	325,000
Office Supply		40,000	40,000
Printing		10,000	10,000
Heat, Light & Water		7,000	7,000
Rent		502,000	502,000
Membership Due		192,000	192,000
Commission Charge		9,000	9,000
Outsourcing Expense		7,270,000	7,270,000
Others		13,000	13,000
Ordinary Expense Total	70,603,500	11,348,000	81,951,500
Ordinary Change before Valuation Gain/Loss	△ 63,711,220	△ 6,754,600	△ 70,465,820
Basic Fund Valuation Gain/Loss	0	0	0
Specific Asset Valuation Gain/Loss	0	0	0
Investment Fund Valuation Gain/Loss	0	0	0
Valuation Gain/Loss Total	0	0	0
Ordinary Change	△ 63,711,220	△ 6,754,600	△ 70,465,820
General Net Assets Change Total	△ 63,711,220	△ 6,754,600	△ 70,465,820